NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Use of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients with Leukocyte Adhesion Deficiency Type 1 (LAD1) who have Inflammatory Pathology

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 12 Years
Max Age: 65 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women


Autosomal Recessive Disorder;
Oral Ulcer;
Cytokine Expression

Recruitment Keyword(s)




Investigational Drug(s)


Investigational Device(s)



Drug: Ustekinumab

Supporting Site

National Institute of Allergy and Infectious Diseases


The disease leukocyte adhesion deficiency type 1 (LAD1) affects white blood cells. Those are immune system cells. In people with LAD1, white blood cells do not properly communicate with the rest of the body. This causes uncontrolled inflammation, particularly in the gums. People with LAD1 can get frequent infections and tend to lose their teeth before adulthood. Researchers want to see if a drug called ustekinumab helps people with LAD1.


To study the safety and tolerability of ustekinumab in treating gum inflammation in people with LAD1.


People ages 12 65 with LAD1


Participants will be screened with:

-Medical history

-Physical exam

-Oral exam

-A scan of the chest, abdomen, and pelvis for possible infection

-Blood and urine tests

The baseline visit will take 2 days. Participants will:

-Repeat most screening tests

-Have a skin exam

-Have small pieces of their gums removed (biopsy)

-Have mouth fluids collected

-Get the study drug injected under the skin of the abdomen, thigh, or elsewhere on the body. They will be watched for at least 2 hours.

Participants will be instructed on tracking how they are feeling and any side effects.

Participants will have 4 more visits over 40 weeks. They will get the study drug and repeat the baseline tests.

Participants may have up to 5 more tissue biopsies.

Participants will be called between visits to discuss how they are feeling and side effects.

Participants will have a final visit 52 weeks after the baseline. They will repeat most of the baseline tests.

Participants will answer questions about their oral ulcers.

--Back to Top--



-Age 12-65 years.

-Molecularly and cellularly confirmed LAD1 with inflammatory lesions.

-Willing to allow storage of biological samples for future research.

-Willing to allow genetic testing of blood samples.

-Able to provide informed consent.

-Participants who can get pregnant or impregnate a partner must agree to use adequate contraception when engaging in sexual activities that can result in pregnancy. Adequate contraception must be used consistently starting at screening and lasting through the final study visit. Appropriate forms of contraception include the following:

a. Intrauterine device or equivalent.

b. Hormonal contraceptive (eg, consistent, timely, and continuous use of contraceptive pill, patch, ring, implant, or injection) that has reached full efficacy before dosing.

c. A double barrier method (eg, male/female condom, cap, or diaphragm plus spermicide).

d. Be in a stable, long-term monogamous relationship, per assessment of the principal investigator (PI), with a partner who does not pose any potential pregnancy risk, eg, has undergone a vasectomy at least 6 months before the first dose of study agent or is of the same sex as the participant.

e. Have had a hysterectomy and/or a bilateral tubal ligation or both ovaries removed.


-History of malignancy (except for basal cell carcinoma) within the previous 5 years.

-Infected with HIV.

-Active uncontrolled bacterial, viral, or fungal infection.

-Active or chronic viral hepatitis.

-Active or latent untreated tuberculosis.

-Received Bacillus Calmette-Guerin vaccine within the last year.

-Received live attenuated vaccines within 15 weeks before the first dose.

-Allergy to any component of the ustekinumab formulation.

-Pregnant or breastfeeding.

-Any condition that, in the opinion of the investigator, contraindicates participation in this study.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Beatriz E. Marciano, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
Building 10
Room 12C103
10 Center Drive
Bethesda, Maryland 20892
(301) 443-8332

Dawn Shaw, R.N.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
Building 10
Room 12C103
10 Center Drive
Bethesda, Maryland 20892
(301) 401-4740

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--